Treatment of Multiple Sclerosis with Cladribine
作者： Jack C. Sipe , J. S. Romine , J. Zyroff , J. Koziol , E. Beutler
DOI: 10.1007/978-1-4471-1271-6_14
关键词: Adenosine 、 Adenosine deaminase 、 Hairy cell leukemia 、 Nucleoside 、 Cladribine 、 Purine nucleoside phosphorylase 、 Medicine 、 Multiple sclerosis 、 Immunology 、 Immunodeficiency
摘要: Cladribine, also known as 2-chlorodeoxyadenosine (2-CdA) or Leustatin®, is an adenosine deaminase-resistant purine nucleoside that selectively targets lymphoid cells, with relatively low toxicity toward other tissues (Beutler 1992). The history of the development cladribine begins discovery a relationship between severe combined immunodeficiency disease (SCID) lymphopenia and inherited deficiency enzyme deaminase (ADA). ADA was discovered serendipitously by Giblett et al. in 1972 while investigating linkage to variety genetic markers. For many years SCID results from complete not understood.
springer.com
sci-hub.st 参考文章(31)
R. A. C. Hughes, Pathogenesis of multiple sclerosis. Journal of the Royal Society of Medicine. ,vol. 85, pp. 373- 376 ,(1992)
DA Carson, DB Wasson, R Taetle, A Yu, Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes Blood. ,vol. 62, pp. 737- 743 ,(1983) , 10.1182/BLOOD.V62.4.737.737
A Saven, CJ Carrera, DA Carson, E Beutler, LD Piro, 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. ,vol. 80, pp. 587- 592 ,(1992) , 10.1182/BLOOD.V80.3.587.BLOODJOURNAL803587
William R. Crom, Victor M. Santana, Raymond L. Blakley, Christine M. Kearns, Pharmacokinetics of Cladribine (2-Chlorodeoxyadenosine) in Children with Acute Leukemia Cancer Research. ,vol. 54, pp. 1235- 1239 ,(1994)
A C Kay, A Saven, C J Carrera, D A Carson, D Thurston, E Beutler, L D Piro, 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. Journal of Clinical Oncology. ,vol. 10, pp. 371- 377 ,(1992) , 10.1200/JCO.1992.10.3.371
2-chlorodeoxyadenosine for Patients With B-cell Chronic Lymphocytic-leukemia Resistant To Fludarabine The New England Journal of Medicine. ,vol. 328, pp. 812- 813 ,(1993) , 10.1056/NEJM199303183281116
Ernest Beutler, James A. Koziol, Robert McMillan, Jack C. Sipe, John S. Romine, Carlos J. Carrera, Marrow suppression produced by repeated doses of cladribine. Acta Haematologica. ,vol. 91, pp. 10- 15 ,(1994) , 10.1159/000204236
JC Sipe, JS Romine, JA Koziol, R McMillan, E Beutler, J Zyroff, Cladribine in treatment of chronic progressive multiple sclerosis The Lancet. ,vol. 344, pp. 9- 13 ,(1994) , 10.1016/S0140-6736(94)91046-4
D. A. Carson, J. Kaye, J. E. Seegmiller, Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s) Proceedings of the National Academy of Sciences of the United States of America. ,vol. 74, pp. 5677- 5681 ,(1977) , 10.1073/PNAS.74.12.5677
Lawrence Jacobs, Donald E. Goodkin, Richard A. Rudick, Robert Herndon, Advances in specific therapy for multiple sclerosis Current Opinion in Neurology. ,vol. 7, pp. 250- 254 ,(1994) , 10.1097/00019052-199406000-00012